CMPX Compass Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1738021 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-31.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-49.0%
ROA-42.6%
ROIC (approx.)-56.2%
Asset turnover—
Leverage & solvency
Liabilities / assets18.3%
Debt / equity0.00x
Current ratio6.79x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio-12.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $850,000 | $0 | — | — |
| R&D expense | $55.97M | $42.34M | $38.12M | $30.00M | $20.34M |
| SG&A expense | $16.87M | $15.13M | $12.24M | $11.66M | $10.93M |
| Operating income | -$72.84M | -$56.62M | -$50.36M | -$41.66M | -$81.88M |
| Interest expense | — | — | — | $0 | $370,000 |
| Pretax income | — | — | -$42.49M | -$39.23M | -$82.18M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$66.49M | -$49.38M | -$42.49M | -$39.23M | -$82.18M |
| EBITDA | -$72.56M | -$56.04M | -$49.66M | -$40.87M | -$81.32M |
| EPS (basic) | -0.42 | -0.36 | -0.33 | -0.37 | -1.31 |
| EPS (diluted) | — | — | — | — | -1.31 |
| Weighted avg. shares (diluted) | — | 137.40M | — | — | 62.87M |
| Balance sheet | |||||
| Cash & equivalents | $30.64M | $43.48M | $24.23M | $34.95M | $144.51M |
| Short-term investments | $178.26M | $83.24M | $128.23M | $151.66M | $0 |
| Current assets | $209.82M | $132.75M | $153.88M | $194.79M | $147.10M |
| PP&E, net | $102,000 | $353,000 | $898,000 | $1.57M | $2.24M |
| Total assets | $219.59M | $140.40M | $156.88M | $199.65M | $153.76M |
| Current liabilities | $13.97M | $8.87M | $7.80M | $16.17M | $10.63M |
| Short-term debt | — | — | — | — | $0 |
| Long-term debt | — | — | — | — | $0 |
| Total debt | — | — | — | — | $0 |
| Total liabilities | $22.80M | $15.17M | $8.34M | $18.01M | $13.68M |
| Shareholders' equity | $196.79M | $125.23M | $148.54M | $181.64M | $140.08M |
| Net debt | — | — | — | — | -$144.51M |
| Shares outstanding | 178.32M | 137.82M | 127.67M | 126.30M | 100.83M |
| Cash flow statement | |||||
| Operating cash flow | -$49.14M | -$44.85M | -$40.62M | -$34.12M | -$19.67M |
| Capital expenditure | $25,000 | $44,000 | $30,000 | $212,000 | $1.57M |
| Free cash flow | -$49.17M | -$44.90M | -$40.65M | -$34.34M | -$21.23M |
| Investing cash flow | -$93.31M | $46.77M | $26.96M | -$151.20M | -$1.77M |
| Financing cash flow | $129.61M | $17.34M | $2.94M | $75.76M | $118.61M |
| Depreciation & amortization | $276,000 | $589,000 | $699,000 | $782,000 | $566,000 |
| Stock-based compensation | $8.37M | $8.56M | $6.12M | $5.33M | $4.03M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.